Evidence map›Paper›PMID 21266983›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2011

Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study.

Francisco Campos, Tomás Sobrino, Pedro Ramos-Cabrer, Bárbara Argibay, Jesús Agulla, María Pérez-Mato, Raquel Rodríguez-González, David Brea, José Castillo

Open access · greenAbstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 140 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke.International journal of molecular sciences · 2024
    Observational
  6. Review
  7. Article
  8. Article
  9. Biomarkers and the outcomes of ischemic stroke.Frontiers in molecular neuroscience · 2023
    Review
  10. Article
  11. Review
  12. Increased high-mobility group box 1 levels are associated with depression after acute ischemic stroke.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Francisco CamposDepartment of Neurology, Clinical Neuroscience Research Laboratory, Hospital Clínico Universitario, University of Santiago de Compostela, IDIS, Santiago de Compostela, Spain. francampos@linc-stg.eu
Tomás Sobrino
Pedro Ramos-Cabrer
Bárbara Argibay
Jesús Agulla
María Pérez-Mato
Raquel Rodríguez-González
David Brea
José Castillo
Universidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As ischemic stroke is associated with an excessive release of glutamate into the neuronal extracellular space, a decrease in blood glutamate levels could provide a mechanism to remove it from the brain tissue, by increasing the brain-blood gradient. In this regard, the ability of glutamate oxaloacetate transaminase (GOT) to metabolize glutamate in blood could represent a potential neuroprotective tool for ischemic stroke. This study aimed to determine the neuroprotective effects of GOT in an animal model of cerebral ischemia by means of a middle cerebral arterial occlusion (MCAO) following the Stroke Therapy Academic Industry Roundtable (STAIR) group guidelines. In this animal model, oxaloacetate-mediated GOT activation inhibited the increase of blood and cerebral glutamate after MCAO. This effect is reflected in a reduction of infarct size, smaller edema volume, and lower sensorimotor deficits with respect to controls. Magnetic resonance spectroscopy confirmed that the increase of glutamate levels in the brain parenchyma after MCAO is inhibited after oxaloacetate-mediated GOT activation. These findings show the capacity of the GOT to remove glutamate from the brain by means of blood glutamate degradation, and suggest the applicability of this enzyme as an efficient and novel neuroprotective tool against ischemic stroke.

Indexed as

AnimalsAspartate AminotransferasesBrainBrain IschemiaCells, CulturedEndothelial CellsEnzyme ActivationGlutamic AcidInfarction, Middle Cerebral ArteryMagnetic Resonance ImagingMaleNeuroprotective AgentsOxaloacetic AcidRatsRats, Sprague-DawleyAspartate AminotransferasesGlutamic AcidNeuroprotective AgentsOxaloacetic Acid

Identifiers

PMID21266983
PMCPMC3130324
OpenAlexW1991479116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.